Printer Friendly

NEWS REPORTS MISINTEREST PRESCRIBING INFORMATION FOR STROKE DRUG SAYS SYNTEX CORPORATION

 NEWS REPORTS MISINTEREST PRESCRIBING INFORMATION FOR STROKE DRUG
 SAYS SYNTEX CORPORATION
 NEW YORK, Aug. 13 /PRNewswire/ -- Syntex Corporation reports that The indications for Ticlid(R) (ticlopidine hydrochloride) -- to reduce stroke risk in patients who have experienced stroke precursors or who are at risk of recurrent stroke -- have been widely misinterpreted in many news reports to imply that the drug is second-line therapy in all cases. This misinterpretation may deprive appropriate patients of a potentially beneficial therapy.
 Ticlid is appropriate first-line therapy to reduce stroke risk for women who have experienced a stroke warning sign, known as a TIA (transient ischemic attack), and for men and women to reduce the risk of another stroke if they have already had a stroke. Ticlid is appropriate second-line therapy only for male patients who have experienced a stroke warning sign; however, if these patients are intolerant to aspirin, Ticlid is appropriate first-line therapy.
 The confusion is understandable. The prescribing information for Ticlid states that because Ticlid is associated with a risk of neutropenia, a serious side effect, it "should be reserved for patients who are intolerant to aspirin therapy where indicated to prevent stroke." The prescribing information for aspirin states that aspirin is indicated for reducing the risk of recurrent TIAs and initial strokes in men only.
 Ticlid is the first prescription drug approved for marketing to reduce the risk of stroke, the nation's third leading cause of death and the leading cause of adult disability. Each year 500,000 people suffer strokes in the United States. Approximately 150,000 of them die. Strokes will take the lives of 90,000 American women this year. It is the second leading cause of death among women. As a cause of death, it is more common than breast cancer. Ticlid is the first and only drug indicated to reduce stroke risk in women.
 Ticlid was shown in a major study of more than 3,000 patients to be 48 percent more effective than aspirin at reducing the risk of initial stroke in men and women during the first year after a TIA (whose symptoms include transient weakness on one side of the body, slurring of speech, or fleeting loss of vision in one eye) -- the period of greatest danger. In a study of more than 1,000 patients who had already had a stroke, Ticlid was also shown to reduce the risk of another stroke by 33 percent during the first year. As the only medication indicated to reduce the risk of recurrent stroke, Ticlid offers hope to the nearly 3 million stroke survivors in the United States.
 Patients using Ticlid require blood count monitoring before starting therapy, and at least every two weeks during the first three months of medication, to detect the possible occurrence of neutropenia (a condition in which white blood cells are reduced). Through support from Syntex Laboratories, Inc., manufacturer of the drug, the laboratory service for the tests is available to all patients at no additional cost, although patients are not obligated to use this special service.
 -0- 8/13/92
 /CONTACT: Linda Thomas of Syntex, 415-852-1321, or Maureen Galvin of GTFH Public Relations, 212-886-3129, for Syntex/ CO: Syntex Corporation ST: California IN: MTC SU:


TS-OS -- NY029 -- 9526 08/13/92 10:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1992
Words:543
Previous Article:CCA TO ISSUE STOCK WARRANTS
Next Article:ELECTROMEDICS, HCA HOSPITAL CORPORATION OF AMERICA AND QUORUM HEALTH RESOURCES ANNOUNCE JOINT AGREEMENT
Topics:


Related Articles
NEW DRUG SIGNIFICANTLY REDUCES THE RISK OF STROKE -- NATION'S THIRD LEADING CAUSE OF DEATH
FDA COMPLETES REVIEW OF CARDENE SR
SYNTEX SECOND QUARTER E.P.S. UP 20 PERCENT; FIRST HALF E.P.S. UP 12 PERCENT
SYNTEX RECEIVES FDA APPROVAL TO MARKET CARDENE(R) SR FOR TREATING HYPERTENSION
FDA APPROVES MARKETING OF SYNTEX'S CYTOVENE FOR ADDITIONAL INDICATION -- PREVENTION OF CMV INFECTION IN TRANSPLANT PATIENTS
'WE'RE INVESTING NOW FOR FUTURE GROWTH,'SYNTEX TELLS ANALYSTS
SYNTEX ACQUIRES EXCLUSIVE RIGHTS TO MARKET ELAN'S ONCE-DAILY NAPROXEN FORMULATION IN UNITED STATES
SYNTEX ACQUIRES EXCLUSIVE RIGHTS TO MARKET ELAN'S ONCE-DAILY NAPROXEN FORMULATION IN UNITED STATES
FURTHER DETAILS ON SYNTEX MEETING WITH SECURITIES ANALYSTS
SYNTEX RECEIVES CLEARANCE FOR ENTERIC-COATED EC-NAPROSYN(TM) IN THE UNITED STATES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters